An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Recruiting now · Phase 3

Conditions studied: Breast Cancer, Early Breast Cancer

In brief

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.

Key facts

Study ID: NCT05952557
Run by: AstraZeneca
People needed: 5500
Starts: 2023-10-05
Expected to finish: 2037-05-06
Last updated by the study team: 2026-06-25

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Women and Men; ≥18 years at the time of screening (or per national guidelines)
Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with absence of any evidence of metastatic disease as defined in the protocol.
Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy.
Patients must be randomised within 12 months of definitive breast surgery.
Patients may have received up to 12 weeks of endocrine therapy prior to randomisation.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
Adequate organ and bone marrow function

You may not qualify if…

Inoperable locally advanced or metastatic breast cancer
Pathological complete response following treatment with neoadjuvant therapy
History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix or considered a very low risk of recurrence per investigator judgement) unless in complete remission with no therapy for a minimum of 5 years from the date of randomisation
Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion precludes participation in the study or compliance "
Known LVEF <50% with heart failure NYHA Grade ≥2.
Mean resting QTcF interval > 480 ms at screening
Concurrent exogenous reproductive hormone therapy or non topical hormonal therapy for non-cancer-related conditions
Any concurrent anti-cancer treatment not specified in the protocol with the exception of bisphosphonates (e.g. zoledronic acid) or RANKL inhibitors ( eg, denosumab)
Previous treatment with camizestrant, investigational SERDs/investigational ER targeting agents, or fulvestrant
Currently pregnant (confirmed with positive serum pregnancy test) or breastfeeding.
Patients with known hypersensitivity to active or inactive excipients of camizestrant or drugs with a similar chemical structure or class to camizestrant. In pre-/peri-menopausal female and male patients, known hypersensitivity or intolerance to LHRH agonists that would preclude the patient from receiving any LHRH agonist.

Where it is running

Research Site — Plantation, Florida, United States (enrolling)
Research Site — West Palm Beach, Florida, United States (enrolling)
Research Site — Plantation, Florida, United States (enrolling)
Research Site — Phoenix, Arizona, United States (enrolling)
Research Site — St. Petersburg, Florida, United States (enrolling)
Research Site — Dothan, Alabama, United States (enrolling)
Research Site — Irvine, California, United States (enrolling)
Research Site — Fayetteville, Arkansas, United States (enrolling)
Research Site — Los Angeles, California, United States (enrolling)
Research Site — Duarte, California, United States (enrolling)
Research Site — Fountain Valley, California, United States (enrolling)
Research Site — West Hollywood, California, United States (enrolling)
Research Site — Tucson, Arizona, United States (enrolling)
Research Site — Littleton, Colorado, United States (enrolling)
Research Site — Littleton, Colorado, United States (enrolling)
Research Site — New Haven, Connecticut, United States (enrolling)
Research Site — Newark, Delaware, United States (enrolling)
Research Site — La Jolla, California, United States (enrolling)
Research Site — Clearwater, Florida, United States (enrolling)
Research Site — Fort Myers, Florida, United States (enrolling)
Research Site — Gainesville, Florida, United States (enrolling)
Research Site — Jacksonville, Florida, United States (enrolling)
Research Site — Walnut Creek, California, United States (enrolling)
Research Site — Pembroke Pines, Florida, United States (enrolling)
Research Site — Atlanta, Georgia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.